Around the world, children are far more likely than ever before to develop food allergies.
Recent inquiries into the deaths of two British teenagers after eating sesame and peanut highlighted the sometimes tragic consequences. In August, a six-year-old girl in Western Australia died as the result of a dairy allergy.
The rise in allergies in recent decades has been particularly noticeable in the West. Food allergy now affects about 7 percent of children in the UK and 9 percent of those in Australia, for example. Across Europe, 2 percent of adults have food allergies.
Allergy Therapeutics (LON:AGY) is an international commercial biotechnology group focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.
